An open-loop insulin delivery device for the control of experimental diabetes. 1979

A M Albisser, and W S Jackman, and R Ferguson, and A Bahoric, and Y Goriya

A new insulin delivery device has been developed and tested. It includes a reservoir, a pump, and a power pack. The reservoir holds 75 ml and is coupled to a precision peristaltic pump whose delivery can be set to any one of 128 different flow rates from 0 to 80 microliter/min (+/- 1.6% over 10 months) using the flow rate controller included in the battery power pack. The system weighs 525 g, consuming 50 mW at the maximum pumping rate, proportionately less at lower rates. Ten pumps have undergone bench tests for 30 days. One has been subjected to an extended life test of 16 months without change of tubing while seven complete systems have been used on dogs to demonstrate their capability for precise long-term (up to 16 months) intravenous insulin therapy. With this system, experimental diabetes has been controlled in 7 dogs for periods now extending beyond 16 months. This device now qualifies for-long term studies on hospitalized patients with diabetes mellitus.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007515 Islets of Langerhans Irregular microscopic structures consisting of cords of endocrine cells that are scattered throughout the PANCREAS among the exocrine acini. Each islet is surrounded by connective tissue fibers and penetrated by a network of capillaries. There are four major cell types. The most abundant beta cells (50-80%) secrete INSULIN. Alpha cells (5-20%) secrete GLUCAGON. PP cells (10-35%) secrete PANCREATIC POLYPEPTIDE. Delta cells (~5%) secrete SOMATOSTATIN. Islands of Langerhans,Islet Cells,Nesidioblasts,Pancreas, Endocrine,Pancreatic Islets,Cell, Islet,Cells, Islet,Endocrine Pancreas,Islet Cell,Islet, Pancreatic,Islets, Pancreatic,Langerhans Islands,Langerhans Islets,Nesidioblast,Pancreatic Islet
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001187 Artificial Organs Devices intended to replace non-functioning organs. They may be temporary or permanent. Since they are intended always to function as the natural organs they are replacing, they should be differentiated from PROSTHESES AND IMPLANTS and specific types of prostheses which, though also replacements for body parts, are frequently cosmetic (EYE, ARTIFICIAL) as well as functional (ARTIFICIAL LIMBS). Artificial Organ,Organ, Artificial,Organs, Artificial

Related Publications

A M Albisser, and W S Jackman, and R Ferguson, and A Bahoric, and Y Goriya
October 2007, Issues in emerging health technologies,
A M Albisser, and W S Jackman, and R Ferguson, and A Bahoric, and Y Goriya
October 2018, Lancet (London, England),
A M Albisser, and W S Jackman, and R Ferguson, and A Bahoric, and Y Goriya
April 1975, Biomedizinische Technik. Biomedical engineering,
A M Albisser, and W S Jackman, and R Ferguson, and A Bahoric, and Y Goriya
January 1980, Acta diabetologica latina,
A M Albisser, and W S Jackman, and R Ferguson, and A Bahoric, and Y Goriya
January 1980, Diabetes care,
A M Albisser, and W S Jackman, and R Ferguson, and A Bahoric, and Y Goriya
January 1981, Medical instrumentation,
A M Albisser, and W S Jackman, and R Ferguson, and A Bahoric, and Y Goriya
June 2015, Best practice & research. Clinical endocrinology & metabolism,
A M Albisser, and W S Jackman, and R Ferguson, and A Bahoric, and Y Goriya
March 2020, The Journal of pediatrics,
A M Albisser, and W S Jackman, and R Ferguson, and A Bahoric, and Y Goriya
January 1980, Diabetes care,
A M Albisser, and W S Jackman, and R Ferguson, and A Bahoric, and Y Goriya
May 2019, The Lancet. Digital health,
Copied contents to your clipboard!